All lobbying filings

THE NICKLES GROUP, LLC

Lobbying for NOVO NORDISK, INC. · Pharmaceutical company.

Filing 3rd Quarter - Report

3rd Quarter (July 1 - Sep 30) 2025 · District of Columbia · House · Senate · $80,000.00 income · posted Oct 16, 2025

Official filing document

Bills named in this filing 4

HR 1492
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic can…
HR 1
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
HR 591
Defending American Jobs and Investment Act
HR 2423
Unfair Tax Prevention Act

Lobbying activity 4

Health Issues

Issues related to compounding and counterfeit drugs.

Medicare/Medicaid

Issues related to drug pricing and implementation of the Inflation Reduction Act. H.R. 1492, the Ensuring Pathways to Innovative Cures Act. Issues related to coverage of anti-obesity medications. H.R. 1 (P.L. 119-21), One Big Beautiful Bill Act, as it relates to drug pricing and pharmacy benefit management reforms. Issues related to Most Favored Nation drug pricing.

Taxation/Internal Revenue Code

H.R. 1 (P.L. 119-21), One Big Beautiful Bill Act, as it relates to corporate taxes and foreign-based multinationals. H.R. 591, Defending American Jobs and Investment Act, and H.R. 2423, Unfair Tax Prevention Act, as they relate to multinational corporations.

Trade (domestic/foreign)

Issues related to tariffs. Issues related to importation of counterfeit drugs.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.